Background. There is a lack of new therapeutic strategies for IgA nephropathy. Low-dose sirolimus inhibits mesangial cell proliferation and renal fibrosis in animal models. Methods. We performed a pilot, randomized controlled trial to evaluate the efficacy and safety of low-dose sirolimus in patients with a high-risk IgA nephropathy. Twentythree patients with a glomerular filtration rate (GFR) within 30-60 mL/min and/or proteinuria >1 g/day were randomly assigned to low-dose sirolimus plus enalapril and atorvastatin (SRL group, n ¼ 14) or enalapril plus atorvastatin (CONTROL group, n ¼ 9). Primary composite end point was variation of haematuria, proteinuria and blood pressure. Secondary end points were isotopic GFR, renal histology evaluated by Oxford classification and safety parameters evaluated at 6 and 12 months. Results. Primary end point improved significantly in the SRL group at 12 months. Regarding isotopic GFR, patients included in the CONTROL group lost 8 mL/min/ 1.73m 2 , whereas those in the SRL arm improved 5 mL/ min/1.73m 2 (P ¼ 0.03). Proteinuria decreased similarly in both study groups. At 1 year, SRL treatment was associated with a significant reduction of mesangial and endocapillary proliferation, whereas glomerular sclerosis, tubular atrophy and interstitial fibrosis were similar. Sirolimus was well tolerated; all patients remained on therapy at 12 months. Conclusion. The addition of low-dose sirolimus to enalapril and statin is safe, stabilizes renal function and reduces glomerular proliferative lesions in patients with poor prognosis IgA nephropathy.
Introduction
IgA nephropathy (IgAN) is the most frequent glomerulonephritis worldwide. In Mediterranean countries, Asia and Australia, its prevalence among primary glomerulonephritis is 20-40%, whereas in countries such as Great Britain, Canada or the USA, it is 2-10% [1] . In Spain, IgAN is also the most frequent glomerulonephritis with an annual incidence of 7.9 cases per million population [2] .
The primary form of the disease was considered quite harmless for years. However, some data suggest that IgAN is not as benign as previously regarded. IgAN is the first cause of end-stage renal disease among patients with primary glomerulonephritis [1] . Also, after 20 years of followup, 15-40% of patients with IgAN develop end-stage renal disease and an additional 20% show progression of kidney damage [1, 3, 4] . Finally, clinical and histological recurrence of IgAN is frequent after renal transplantation, even though allograft recipients are receiving potent immunosuppressive medications [1, 4] .
Some prognostic markers associated with the progression of renal disease in IgAN are male sex, hypertension, proteinuria >0.5 g/day and decline of glomerular filtration rate (GFR) [1, 4] . Different therapeutic approaches have been tested in IgAN [5] . Among these treatments are angiotensin-converting enzyme inhibitors (ACEIs) [6] , statins [7] , n-3 polyunsaturated fatty acids [8] , corticoids [9] and several immunosuppressive combinations [10] . However, there will be few recommendations for the treatment of IgAN in the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on the treatment of glomerular disease that are going to be published in 2011 [4] . In fact, supportive care with ACEI or angiotensin receptor blocker (ARB) will be recommended unless the patient exhibits a rapidly progressive IgAN course [4] .
Rapamycin or Sirolimus (SRL) is a macrolide with immunosuppressive capacity. The SRL-FK-binding protein complex inhibits mTOR (mammalian target of rapamycin), which is crucial for cellular growth and proliferation [11] . Some studies have reported controversial experiences with SRL in several types of glomerulonephritis in humans. A team from Emory University included 21 patients with focal and segmental glomerulosclerosis and showed a decrease in proteinuria and serum creatinine after starting on SRL in 19% of patients [12] . In Mayo Clinic, 11 patients with several types of glomerulonephritis were treated with SRL, 5 of 11 had IgAN. There was an impairment of renal function after a full-dose of SRL in those patients with severe renal insufficiency [13] . However, there are experimental data suggesting that low-dose SRL can be beneficial in IgA nephropathy. First, Wang et al. [14] showed that SRL, at concentrations between 10-1000 nM, inhibited mesangial proliferation derived from platelet-derived growth factor, whereas this effect appeared with tacrolimus concentrations >10000 nM. Second, Lock et al. [15] showed that low-dose SRL (0.1-0.001 ng/mL) inhibited mesangial cell proliferation and collagen IV production. Finally, Krämer et al. [16] demonstrated that low-dose SRL attenuated anti-thy1 glomerulonephritis in the rat.
The objective of the present pilot study was to explore the efficacy and safety of the administration of low-dose SRL in patients with primary IgA nephropathy with poor prognosis markers. Patients were randomized into two treatment groups, one with and the other without SRL, both receiving treatment with ACEI and a statin. SRL was administered targeting lower levels than those achieved in the transplantation setting. Baseline and 1-year protocol biopsies were evaluated applying the Oxford classification of IgAN [17] .
Materials and methods

Study population
This was an investigator promoted, prospective, multicentre open-label randomized pilot study performed in patients with high risk IgAN. The study was approved by The Spanish Drug Agency (EudraCT 2005-002610-37) and registered in Clinical Trials (NCT 00396721).
Inclusion criteria were 18-to 70-year-old patients if they had a biopsyproven IgA nephropathy diagnosed in the previous 3 months; absence of known hepatic, cardiac, pulmonary or intestinal disease; GFR estimated by Cockroft-Gault formula within 30-60 mL/min/1.73m 2 ; proteinuria >1 g/ day; hypertension defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg associated with proteinuria between 0.3-1 g/day.
Exclusion criteria were positive serology for human immunodeficiency virus or hepatitis B virus infection (defined as positive for the HBsAg antigen) or hepatitis C virus infection (defined as viral RNA detection); treatment with steroids or any other immunosuppressant in the two previous years; evidence of active infection; pregnancy at the time of inclusion in the study; GFR < 30 mL/min/1.73m 2 ; serum bilirubin > 2 mg/dL; alanine amino transferase aspartate amino transferase two times higher than the normal upper limit; diabetes mellitus, defined as patients treated with insulin or oral antidiabetic agents or serum basal glucose >140 mg/ dL in two or more determinations; poor controlled hypertension (defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg, taking three or more antihypertensive drugs) or evidence or suspicion of renovascular disease; thrombocytopenia <100 000/mm 3 or total neutrophil counts <2000/mm 3 ; triglycerides >4.6 mmol/L; cholesterol >7.8 mmol/L; low density lipoprotein (LDL) >5.2 mmoL; systemic IgAN forms, i.e. Schönlein-Henoch purpura, IgAN secondary forms; cases presented in the form of rapidly progressive renal failure; extra capillary proliferation >50% at renal biopsy; use of any other medication under research; cancer diagnosis in the five previous years, except suitably removed skin basal cell carcinoma; known intolerance to SRL or macrolides.
Study groups
After giving informed consent, patients were randomly assigned to Group I (SRL 1 enalapril 1 atorvastatin; the SRL treatment) or Group II (enalapril 1 atorvastatin; the CONTROL treatment). The randomization approach was permuted-block randomization with a block size of six and an allocation ratio of 1:1. Initial SRL dose (RapamuneÒ; Wyeth) was 1 mg/ day. SRL blood level was monitored and dose adjusted to be within 4-8 ng/mL. Patients also received an ACEI and a statin. Patients not receiving ACEI began enalapril 5 mg/day. Patients receiving an ACEI other than enalapril were allowed to continue with it, although it was recommended to change to enalapril whenever possible. Enalapril dose and the addition of other antihypertensive medications was managed in order to achieve target blood pressure <130/80 mmHg. As statin, we used atorvastatin, starting at 10 mg/day. Patients receiving a statin other than atorvastatin were allowed to continue with it, although it was recommended to change to atorvastatin whenever possible. Statin dose was properly adjusted to reduce total cholesterol levels <4.2 mmol/L.
Primary and secondary efficacy end points Primary end point.. Composite clinical variable resulting from evolution of proteinuria, blood pressure and haematuria measured at Month 6 and 12. At baseline, each patient had 6 points (2 for proteinuria, 2 for blood pressure, 2 for haematuria). At 6 months, any change in these parameters was reflected in the score as 11, 0 or À1, depending on improving, no change or worsening in comparison to baseline. The same was done at 12 months in comparison to the 6-month values. So, for each patient, there was a final 12-month score that ranged from 0 (worsening of all three variables at 6 and 12 months) to 12 (improvement of all three variables at 6 and 12 months). For proteinuria, change (AE1) was considered when there was variation !30% respect to the previous one in grams per day. For blood pressure, change (AE1) was considered when there was modification in the number of antihypertensive medications and/or !10% variation in mean arterial pressure respect to the previous one. For haematuria; change was considered when there was variation in the semiquantitative colourimetric evaluation of the urine (0, 11, 12, 13, 14).
Secondary end points.. GFR evaluated by means of radionuclide techniques ( 51 Cr-EDTA) at months 6 and 12. Renal histology at baseline and at 12 months blindly evaluated applying the Oxford classification of IgAN [17] . Percentage of cases requiring study drug discontinuation because of adverse events. Percentage of patients with therapeutic failure defined as treatment with steroids, cyclophosphamide, mycophenolate, tacrolimus, cyclosporine or any other immunosuppressant; crescents occurring in >50% of the glomeruli; occurrence of rapidly progressive renal failure; dialysis requirements or renal transplantation.
Statistical analysis
The differences in the categorical variables between both groups were calculated by means of the v 2 test or the Fisher's exact test. The differences in the quantitative variables including the main variable between groups were calculated by means of the Student's t-test or the Mann-Whitney U-test. A P-value <0.05 was considered significant for all test. Results were depicted as mean AE SD.
Results
Enrolment began on 21 July 2006 and closed on 21 July 2008. The last enrolled patient ended treatment on 17 August 2009. All incident patients with IgA nephropathy fulfilling the inclusion criteria were considered in the participating centres (Hospital de Bellvitge, Hospital Germans Trias i Pujol and Fundació Puigvert). The initial recruitment period was estimated to be 1 year and then extended to one additional year in order to achieve the recruitment target of 30 patients. After 2 years, 23 patients were enrolled. Taking into account the pilot nature of the study and that there were 14 patients in the SRL arm, we decided to end recruitment. Patient baseline characteristics are shown in Table 1 . Both study groups were comparable regarding age, renal function, proteinuria, haematuria, blood pressure, interstitial fibrosis and tubular atrophy, body mass index, albumin, cholesterol, triglycerides, uric acid and haemoglobin (Table 2) .
Study outcome
There were 14 patients enrolled in the SRL arm. Mean SRL blood levels were 3.7 (range 2-7.4), 4.1 (range 2-8.2) and 4.7 ng/mL (range 3-8.6) at 3, 6 and 12 months, respectively. All patients were receiving atorvastatin. Atorvastatin dose ranged from 10 to 40 mg/day in both groups (mean atorvastin dose at 12 months was 17.5 AE 10.4 and 17.9 AE 12.5 mg/day in CONTROL and SRL groups, respectively). Enalapril dose ranged from 5 to 20 mg/day in both groups (mean enalapril dose at 12 months was 16.7 AE 5 and 15.7 AE 7.3 mg/day in CONTROL and SRL groups, respectively). The evolution of some clinically relevant variables not included as study end points are presented in Table 2 . There was some reduction of cholesterol in both study groups although most patients did not achieve target levels <4.2 mmol/L.
Efficacy results
Primary composite end point (variation in blood pressure, proteinuria and haematuria) was calculated for each patient at 6 months and at 1 year (Figure 1) . At 6 months, both groups remained unchanged. Nevertheless, the SRL group showed a significant improvement of the composite end point at 1 year. Mean arterial pressure was similar in both groups and remained stable during the study follow-up (Table 3 ). Seventy per cent of patients in each group required the addition of another antihypertensive agent (mainly calcium channel blocker and/or diuretic). No patient received therapy with ACEI in combination ARB. Proteinuria was >1 g/day in most patients included in this study (Table 1) . Both study groups experienced a similar decrease in proteinuria at 6 months and at 1 year of followup (Table 3 ). This effect was probably related to ACEI concomitant treatment. Interestingly, the administration of low-dose SRL in combination with enalapril and atorvastatin was not associated with exacerbation of proteinuria in any patient. At 1 year percentage of patients with !13 of semiquantitative microhaematuria was 50% in the SRL group and 78% in the CONTROL group (Table 3) . Isotopic GFR. Baseline GFR was similar in both study groups, all patients showing some degree of renal insufficiency. The CONTROL group experienced a GFR decrease of 8 mL/min/1.73m 2 at 6 months that remained stabilized at 1 year. On the contrary, the SRL group showed a GFR increase of 5 mL/min at 6 months and at 1 year (Figure 2) .
Renal histology. Baseline biopsies were obtained in all patients and 1-year protocol biopsy was performed in 20 patients (eight of nine in the CONTROL group and 12 of 14 in the SRL group). All biopsies were blindly analysed according to the Oxford classification consensus of IgAN (Figure 3-6) . The evolution of segmental glomerulosclerosis ( Figure 4 ) and tubular atrophy-interstitial fibrosis ( Figure 6 ) were similar in both study groups. Nevertheless, the evolution of mesangial ( Figure 3 ) and endocapillary hypercellularity ( Figure 5 ) was clearly modulated by the administration of SRL. After 1 year of low-dose SRL treatment endocapillary proliferation disappeared and the proportion of patients showing mesangial proliferation was reduced by 30%. On the contrary, in the CONTROL group, patients with endocapillary and mesangial hypercellularity increased by 22 and 34%, respectively, after 1-year follow-up.
Safety results
No patient suffered from any serious adverse event during the study follow-up. There were not any kidney biopsy-related complications. In the CONTROL group, one patient was reported to have experienced fever probably related to a flu-like syndrome and other patients experienced reversible hyperkalaemia. In the SRL group, reported adverse events were: reversible hyperkalaemia, prostatic syndrome, unspecific acute gastritis, cholesterol increase (two patients), anaemia, oedema (two patients) and mild facial rash (two patients). No patient suffered from a macrohaematuria episode. Study medication was not discontinued in any patient. All patients were alive and dialysis-free at the end of the study. No patient developed diabetes or required treatment with erythropoiesis-stimulating agents.
Discussion
IgAN is the most common cause of primary glomerulonephritis worldwide [1] . However, little progress has been achieved regarding its treatment, particularly in high-risk patients without rapidly renal function deterioration. Some of the reasons accounting for this gap and future opportunities are clearly stated by Floege and Eitner in a recent editorial commentary [5] .
Despite the fact that many patients with IgAN have a benign form of the disease, there is a well-identified subgroup of patients at risk for renal disease progression, essentially those with loss of GFR and proteinuria >0.5-1 g/day [5] . Therefore, we focused our study in this population. As previous results using SRL in chronic glomerulonephritis are quite controversial [13] , we were particularly cautious in order to exclude patients with extracapillary forms of the disease and having a rapidly progressive IgAN course. Patients included in the study were mostly men, with reduced GFR, proteinuria and with a chronic form of the disease as demonstrated by the histological findings (most patients had glomerular sclerosis, interstitial fibrosis/ tubular atrophy or both in baseline biopsies). We compared standard therapy with ACEI and statin with the addition of low-dose SRL to this regime. Both groups were comparable in terms of renal function, proteinuria, blood pressure and metabolic abnormalities as serum lipids and uric acid. Uric acid and triglycerides were proposed as poor prognosis markers in IgA nephropathy [18] . Previous experiences from our group with low-dose SRL in experimental models prompted us to design this study [19, 20] . SRL has been used for many years to avoid rejection in renal transplantation. However, SRL has many side effects, some of which are dose-related [21] . There is evidence that SRL can exacerbate or even induce proteinuria in transplanted and non-transplanted patients [22] . The mechanism accounting for SRL-induced proteinuria is not well understood. Nevertheless, there are some data suggesting that high SRL concentrations may induce podocyte injury [23] by means of inhibition of vascular endothelial growth factor [24] . On the other hand, low-dose SRL has been associated with outstanding beneficial effects in experimental models of chronic renal disease, the majority of them characterized by renal hypertrophy, interstitial inflammation, tubular atrophy, epithelial to mesenchymal transition and interstitial fibrosis [25] . SRL through its inhibition of the mTOR pathway is able to abrogate all of these pathological mechanisms as recently reviewed by Lieberthal and Levine [25] . Furthermore, Krämer et al. [16] reported that low-dose SRL may limit the progressive course of antithy1-induced renal disease toward chronic glomerulosclerosis, tubulointerstitial fibrosis and renal insufficiency.
The first conclusion of the study is that low-dose SRL in combination with ACEI and statin precluded the decline of renal function and was associated with a significant reduction of mesangial and endocapillary proliferation in renal biopsies performed after 1 year of treatment in high-risk IgAN patients. We used a primary composite end point to evaluate efficacy. Among the three parameters included, blood pressure, proteinuria and haematuria, the last one was the most minimized by the use of SRL. The effect on haematuria was probably a result of the reduction of glomerular proliferative lesions. In vitro studies demonstrated that SRL inhibits mesangial [15] and smooth muscle cell proliferation induced by growth factors [26] . On the other hand, evolution of GFR measured by an isotopic method was different between both study groups. In the CONTROL group, there was an initial loss of 8 mL/min/ 1.73m 2 of GFR that was stabilized at 1 year probably associated with ACEI and statin treatment. On the other hand, the SRL group did not show any loss of GFR during the follow-up. Since there was no impact of SRL treatment on segmental glomerulosclerosis, tubular atrophy and interstitial fibrosis in 1-year renal biopsies, we hypothesize that the improvement of renal function associated with SRL could be due to the reduction of glomerular cell proliferation. Probably, longer follow-up is needed in order to translate the reduction of mesangial and endocapillary proliferation toward the reduction of glomerular sclerosis and interstitial fibrosis. Fig. 3 . Mesangial hypercellurarity. Evaluation of baseline and 1-year protocol biopsies according to the Oxford classification. Mesangial score 0.5 (M0) or >0.5 (M1). In the SRL group, there was a 30% increase of patients displaying M0, whereas in the CONTROL group, there was a 34% increase of patients showing M1. Fig. 2 . Isotopic 51 Cr-EDTA GFR. The SRL group showed a significantly higher GFR at 6 months and at 1 year than the CONTROL group.
In addition, SRL given at low doses was well tolerated during the 1 year of treatment showing an excellent safety profile. Probably, the concomitant administration of statin may abrogate the hyperlipidaemia associated with the use of SRL. In fact, there was a similar and mild reduction of LDL cholesterol levels and triglycerides in both groups. Noteworthy, low-dose SRL did not increase proteinuria. The decline of proteinuria was similar in both groups and it was probably related to the antiproteinuric effect of ACEI [27] . However, the majority of patients maintained proteinuria >1 g/day all along the study period. This might be explained by the degree of renal failure (some patients developed hyperkalaemia after introduction of ACEI) or even by the fact that dual ACEI/ARB blockade was not permitted. Also, blood pressure control was similar in the two groups, both numerically as well as regarding the addition of other antihypertensive medications.
Limitations of the study are sample size and short-term follow-up. Clearly, the assessment of renal function by accurate methods and renal histology can minimize such boundaries. Usually, the slope of renal function decline in IgAN is less pronounced than in other renal diseases Fig. 4 . Segmental glomerulosclerosis. Evaluation of baseline and 1-year protocol biopsies according to the Oxford classification. Present is S1 and absent is S0. There were no significant differences regarding segmental glomerulosclerosis. Fig. 5 . Endocapillary hypercellularity. Evaluation of baseline and 1-year protocol biopsies according to the Oxford classification. Present is E1 and absent is E0. E1 was reduced by 43% in the SRL group and virtually disappeared after 1-year follow-up. On the contrary, the CONTROL group showed a 22% increase of patients depicting E1. Fig. 6 . Tubular atrophy/interstitial fibrosis. Evaluation of baseline and 1-year protocol biopsies according to the Oxford classification. Less than 25% is T0, 26-50% is T1, >50% is T2. The progression of tubular atrophy and interstitial fibrosis was similar in both groups.
lasting years until patients achieve the end-stage renal disease status. Therefore, it is difficult to carry out highlevel evidence studies using hard variables as renal survival. Reliable short-term surrogate end points are needed as suggested by Floege [5] . In this regard, renal histology evaluated according to the Oxford classification of IgAN [17] could be one of such short-term surrogate markers to be used.
In conclusion, this pilot prospective, multicentre randomized study suggests that the addition of low-dose SRL to a standard therapy with ACEI and statin is safe, stabilizes renal function and reduces glomerular cell proliferation in patients with poor prognosis IgAN. These promising results should be confirmed in a larger Phase III trial.
